Published in

Cambridge University Press, Epidemiology and Psychiatric Sciences, (29), 2020

DOI: 10.1017/s204579602000027x

Links

Tools

Export citation

Search in Google Scholar

Esketamine clinical trials: reply to Maju et al.

Journal article published in 2020 by C. Gastaldon ORCID, D. Papola ORCID, G. Ostuzzi ORCID, C. Barbui ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in response to a vivid debate triggered by the marketing authorisation recently granted by this new medicine. In this commentary, we reply to their comments attempting to critically discuss the evidence base needed to obtain regulatory approval.